-
公开(公告)号：US11492594B2
公开(公告)日：2022-11-08
申请号：US16814186
申请日：2020-03-10
Inventor： Wolfram-Hubertus Zimmermann , Malte Tiburcy , James Hudson
Abstract: The present invention provides a new method for producing Engineered Heart Muscle (EHM) under chemically fully defined conditions all compatible with GMP regulations. The resulting human myocardium generates force and shows typical heart muscle properties.
-
2.发明申请公开(公告)号：US20190300858A1
公开(公告)日：2019-10-03
申请号：US16416580
申请日：2019-05-20
Inventor： Wolfram-Hubertus ZIMMERMANN , James HUDSON , Malte TIBURCY
IPC: C12N5/077
Abstract: The present invention is directed to a method for producing bioengineered heart muscle (BHM) from pluripotent stem cells, generally comprising the steps of inducing mesoderm differentiation, cardiac differentiation, and cardiac maturation by directed tissue formation. The method is a robust, serum-free and reproducible way to produce BHM for multiple applications, and is applicable to multiple pluripotent stem cell lines. The present invention is also directed to the BHM produced by the method disclosed herein, as well as to uses of said BHM in pharmacologic and toxicity screenings, and its use in medicine.
-
公开(公告)号：US20180250284A1
公开(公告)日：2018-09-06
申请号：US15758098
申请日：2016-09-08
Applicant: GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN , TEVA PHARMACEUTICAL INDUSTRIES LTD.
Inventor： Volker KNAPPERTZ , Michael HAYDEN , Wolfgang BRÜCK , Stefan NESSLER
IPC: A61K31/4704 , A61K9/00
CPC classification number: A61K31/4704 , A61K9/0053 , C07D217/26
Abstract: The present invention relates in a first aspect to compounds for use in the treatment of leukodystrophy whereby these compounds are quinoline derivatives, e.g. laquinimod. In a further aspect, the present invention relates to methods for the treatment of Leukodystrophy, in particular, peroxisomal disorders including Zellweger syndrome.
-
公开(公告)号：US20250067727A1
公开(公告)日：2025-02-27
申请号：US18453306
申请日：2023-08-21
Inventor： WOLFRAM-HUBERTUS ZIMMERMANN , Maria Patapla Zafeiriou
Abstract: The present invention relates to the field of in vitro 3D modeling of neural tissues, particularly of the brain. There is the need of developing cell culture models of neural tissue that reflect physiological aspects of neural tissues. The present invention provides bioengineered neuronal organoid (BENOs) compositions capable of organizing as a functional neuronal network and methods for modeling a disease of neural tissue and/or for drug design based on phenotypic tissue screening or phenotypic drug screening using the disclosed BENO compositions. The present invention also relates to kits for making the instant BENO compositions.
-
公开(公告)号：US20230390460A1
公开(公告)日：2023-12-07
申请号：US18031805
申请日：2021-10-21
Inventor： Wolfram-Hubertus ZIMMERMANN , Malte TIBURCY , Tim MEYER
CPC classification number: A61L27/3895 , A61L2430/20 , A61L27/3886 , A61L27/52
Abstract: A method for manufacturing a multilayer engineered heart muscle that includes (i) providing a liquid reconstitution mixture in a mould and (ii) culturing the mixture. The method includes a sequential addition of one or more further liquid reconstitution mixtures to obtain a multilayer engineered heart muscle. The muscle ideally has the form of a patch, a pouch, or a cylinder. Furthermore, a multilayer engineered heart muscle having collagen, cardiac myocytes and non-myocytes originating from at least 2 layers is disclosed. The multilayer engineered heart muscle forms the basis for several in vitro and in vivo applications such as the production of a multilayer engineered heart muscle for use in a patient, for example for use in heart repair.
-
Patent Agency Ranking
公开(公告)号：US20230250143A1
公开(公告)日：2023-08-10
申请号：US18164297
申请日：2023-02-03
Applicant: Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin , OptoGenTech GmbH
Inventor： Tobias MOSER , Thomas MAGER , Maria ZERCHE
CPC classification number: C07K14/47 , A61K48/0075 , A61K38/1709 , A61P27/02 , A61P27/16
Abstract: The present invention relates to a mutant ion channel capable of being activated by light (‘light-activated’ ion channel) and having improved properties, nucleic acids and expression vectors encoding the mutant ion channel, cells comprising such nucleic acid or expression vector, devices containing the mutant ion channel, nucleic acid or expression vector as well as respective uses and methods.
-
公开(公告)号：US11384132B2
公开(公告)日：2022-07-12
申请号：US16306652
申请日：2017-06-02
Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. , Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin
Inventor： Ernst Bamberg , Phil Wood , Thomas Mager , Tobias Moser , David Lopez de la Morena
IPC: C07K14/705 , C07K14/405 , A61P27/02 , A61K9/00 , C12N5/079 , C12N15/86 , G01N33/68
Abstract: The invention relates to mutant light-inducible ion channels having improved properties as compared to the parent channel, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells comprising the nucleic acid construct or expression vector, and their respective uses, as well as non-human animals comprising the mutant light-inducible ion channel, the nucleic acid construct or the expression vector as disclosed herein.
-
公开(公告)号：US20220193263A1
公开(公告)日：2022-06-23
申请号：US17559538
申请日：2021-12-22
Inventor： Sebastian Kügler
IPC: A61K48/00 , C07K14/475 , C12N15/86
Abstract: The present invention relates to regulatable adeno-associated virus (AAV) vectors as well as to their use in gene therapy. It further relates to corresponding nucleic acid molecules, host cells, non-human transgenic animals, pharmaceutical compositions and kits.
-
![Conformational-specific antibodies against A[β] oligomers](/abs-image/US/2017/04/11/US09617332B2/abs.jpg.150x150.jpg)
公开(公告)号：US09617332B2
公开(公告)日：2017-04-11
申请号：US14399639
申请日：2013-05-08
Inventor： Thomas Bayer
CPC classification number: C07K16/18 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/76 , G01N33/6896 , G01N2500/02 , G01N2500/10 , G01N2800/2821
Abstract: The present disclosure relates to a conformational specific antibody molecule recognizing a conformational epitope of human trimeric or tetrameric Aβ oligomers, wherein said antibody molecule does not bind human monomeric Aβ 1-42 or human Ap 1-42 dimers; and pharmaceutical and diagnostic compositions comprising said antibody molecule as well as methods using same.
-
公开(公告)号：US12141951B2
公开(公告)日：2024-11-12
申请号：US17768947
申请日：2020-10-14
Inventor： Freddy Silvester Wouters-Bunt , Stephan Hock
Abstract: A method of contrast enhancement of a three-dimensional light sheet microscopy image formed from N individual images each corresponding to a light sheet plane and spaced apart from each other in the z-direction by at least a distance d, the x/y-plane being the light sheet plane and the x-direction being the propagation direction of the light sheet of the light sheet plane, comprising:
Deconvolution of the three-dimensional image in the z-direction, comprising: For each intensity vector of N intensities (Ix,y,1, . . . , Ix,y,N) having the same x/y value, performing a multiplication with a tridiagonal N×N deconvolution matrix, which assigns to each voxel (x, y, n) a correction parameter f1, with which, by the multiplication of the deconvolution matrix with the intensity vector, for a component I(x, y, n) of the intensity vector the intensities Ix, y, n+1 and Ix, y, n−1 of the corresponding voxels of the neighboring image plane are multiplied, before they are subtracted from the intensity value I(x, y, n).
-
-
-
-
-
-
-
-
-
Search Results
31
records
(took 0.027 seconds)
